Variable Baseline y-Glutamylcysteine Synthetase Messenger RNA Expression in Peripheral Mononuclear Cells of Cancer Patients, and Its Induction by Buthionine Sulfoximine Treatment

Cancer Research

Volumn 53, Issue 16, 1993, Pages 3662-3666

  Yao, Kang shen ^a   Godwin, Andrew K ^a   Ozols, Robert F ^a   Hamilton, Thomas C ^a   O'Dwyer, Peter J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTHIONINE SULFOXIMINE; GLUTAMATE CYSTEINE LIGASE; MELPHALAN; MESSENGER RNA;

ADULT; ARTICLE; CANCER CELL; CLINICAL ARTICLE; ENZYME REGULATION; ENZYME SYNTHESIS; FEMALE; GENE EXPRESSION; GENE INDUCTION; HUMAN; MALE; MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RNA TRANSLATION; STEADY STATE; TUMOR RESISTANCE;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; BASE SEQUENCE; BUTHIONINE SULFOXIMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; FEMALE; GLUTAMATE-CYSTEINE LIGASE; HUMAN; MALE; METHIONINE SULFOXIMINE; MOLECULAR SEQUENCE DATA; NEOPLASMS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027297051     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Meister, A., and Anderson, M. E. Glutathione. Annu. Rev. Biochem., 52: 711-760, 1983.
2. Suzukake, K., Petro, B. J., and Vistica, D. T. Reduction in glutathione content of l-PAM resistant LI210 cells confers drug sensitivity. Biochem. Pharmacol., 31: 121-124, 1982.
3. Suzukake, K., Vistica, B. P., and Vistica, D. T. Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem. Pharmacol., 32: 165-167, 1983.
4. Green, J. A., Vistica, D. T., Young, R. C., Hamilton, T. C., Rogan, A. M., and Ozols, R. F. Melphalan resistance in human ovarian cancer: characterization of drug resistant cell lines and potentiation of melphalan cytotoxicity by glutathione depletion. Cancer Res., 44: 5427-5431, 1984.
5. Hosking, L. K., Whelan, R. D. H., Shellaixl, S. A., Bedford, P., and Hill, B. T. An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumor agents shown by a range of human tumor cell lines. Biochem. Pharmacol., 40: 1833-1842, 1991.
6. Behrens, B. C., Hamilton, T. C., Grotzinger, K. R., Whang-Peng, J., Batist, G., Louie, K. G., Knutsen, T., McKoy, W. M., Young, R. C., and Ozols, R. F. Characterization of a cisplatin-resistant human ovarian cancer cell line and its use in evaluation of cisplatin analogs. Cancer Res., 47: 414-418, 1987.
7. Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., and Anderson, M. E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase in glutathione synthesis. Proc. Natl. Acad. Sci. USA, 89: 3070-3074, 1992.
8. Britten, R. A., Green, J. A., and Warenius, H. M. Cellular glutathione (GSH) and glutathione-S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. Int. J. Radiol. Oncol. Biol., 24: 527-531, 1992.
9. Meister, A. Selective modification of glutathione metabolism. Science (Washington, DC), 220: A11-A11, 1983.
10. O'Dwyer, P. J., Hamilton, T. C., Young, R. C., LaCreta, F. P., Carp, N., Tew, K. D., Padavic, K., Comis, R. L., and Ozols, R. F. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J. Natl. Cancer Inst., 84: 264-267, 1992.
11. Meister, A., and Griffith, O. W. Effects of methionine sulfoximine analogs on the synthesis of glutamine and glutathione: possible chemotherapeutic implications. Cancer Treat. Rep., 63: 1115-1121, 1979.
12. Ozols, R. F., Louie, K. G., Plowman, J., Behrens, B. C., Fine, R. L., Dykes, D., and Hamilton, T. C. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem. Pharmacol., 36: 147-153, 1987.
13. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
14. Griffith, O. W. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal. Biochem., 106: 207-212, 1980.
15. Horikoshi, T., Danenberg, K. D., Stadlbauer, T. H. W., Volkenandt, M., Shea, L. C. C., Aigner, K., Gustavsson, B., Leichman, L., Frosing, R., Ray, M., Gibson, N. W., Spears, C. P., and Danenberg, P. V. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res., 52: 108-116, 1992.
16. Ng, S-Y., Gunning, P., Eddy, R., Ponte, P., Leavitt, J., Shons, T., and Kedes, L. Evolution of the functional human 3-actin gene and its multipseudogene family: conservation of non-coding regions and chromosomal dispersion of pseudogenes. Mol. Cell Biol., 5: 2720-2732, 1985.
17. D'Arpa, P., Machlin, P. S., Ratrie, H., III, Rothfield, N. F., Cleveland, D. W., and Eamshaw, W. C. cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-KDa carboxyl-terminal fragment. Proc. Natl. Acad. Sci. USA, 85: 2543-2547, 1988.
18. O'Dwyer, P. J., LaCreta, F. P., Walczak, J., Cox, T., Litwin, S., Hoffman, J. P., Zimmy, M., and Comis, R. L. Phase I/pharmacokinetic/biochemical study of the nitroimada-zole hypoxic cell sensitizer SR2508 (etanidazole) in combination with cyclophosphamide. Br J. Cancer, in press, 1993.
19. Traver, R. D., Horikoshi, T., Danenberg, K. D., Stadlbeaner, T. H. W., Danenberg, P. V., Roos, D., and Gibson, N. W. NAD(P)H quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res., 52: 797-802, 1992.
20. O'Dwyer, P. J., Yao, K. S., Godwin, A. K., and Clayton, M. Effects of hypoxia upon detoxicating enzyme activity and expression in HT29 colon adenocarcinoma cells. Proc. Am. Assoc. Cancer Res., 34: 12, 1993.
21. Ford, P. A., Yao, K-S., and O'Dwyer, P. J. Effects of mitomycin C on expression of DT diaphorase and cytochrome P450 reductase in human colon adenocarcinoma cell lines. Proc. Am. Assoc. Cancer Res., 34: 306, 1993.
22. Clayton, M., Clapper, M. L., Halbhenr, T., and O'Dwyer, P. J. Effect of oltipraz upon the survival and detoxication pathways of human colon adenocarcinoma cells. Proc. Am. Assoc. Cancer Res., 33: 286, 1992.
23. Wattenberg, L. W. Chemoprevention of cancer. Cancer Res., 45: 1-8, 1985.
24. Law, M. R., Hetzel, M. R., and Idle, J. R. Debrisoquine metabolism and genetic predisposition to lung. Br. J. Cancer, 54: 686-687, 1989.
25. Hayashi, S., Watenabe, J., and Kawajiri, K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450 1A1 and mu-class glutathione 5-transferase genes. Jpn. J. Cancer Res., 83: 866-870, 1992.
26. Boobis, A. R., and Davies, D. S. Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br. J. Clin. Pharmacol., 30: 653-656, 1990.